Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Links shared publicly online about this topic.

239
total visits

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene International Sàrl today announced results from a phase II investigator initiated study of REVLIMID (lenalidomide) in combination with Avastin (bevacizumab), docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, Ill.

View full resource at news-medical.net

Tags: Cancer Medication, Colorectal Cancer Medication, Prostate Cancer, Prostate, Men's Health, Avastin, Taxotere, Prednisone